热门期刊： 细胞研究（英文版）、 中华医学杂志（英文版）、国际临床研究杂志 等
瑞巴派特联合艾司奥美拉唑应用于慢性糜烂性胃炎患者中的价值分析
Value analysis of the application of rebamipide combined with esomeprazole in patientswith chronic erosive gastritis
ES评分0
| DOI | 10.12208/j.ijcr.20241243 |
| 刊名 |
International Journal of Clinical Research
|
| 年，卷(期) | 2024, 8(7) |
| 作者 |
|
| 作者单位 |
中山大学附属第三医院 广东广州 ; |
| 摘要 |
研究分析瑞巴派特联合艾司奥美拉唑应用于慢性糜烂性胃炎患者中的价值。方法 选择我院2021年9月至2023年9月收治的60例慢性糜烂性胃炎患者，随机数字表法分为研究组、对照组，各30例。两组患者均接受慢性糜烂性胃炎常规治疗，对照组给予艾司奥美拉唑给药，研究组给予瑞巴派特联合艾司奥美拉唑给药，连续治疗2周，就两组患者治疗效果、治疗前后血清因子水平等进行评定对比。结果 治疗后研究组患者治疗总有效率高于对照组，肿瘤坏死因子-α、白介素-6、白介素-8等血清因子水平低于对照组，差异有统计学意义（P＜0.05）。结论 对慢性糜烂性胃炎患者开展瑞巴派特联合艾司奥美拉唑治疗，在提升疗效、促进血清因子水平改善方面的价值突出。
Objective To study and analyze the value of Rebaptiste combined with esomeprazole in patients with chronic erosive gastritis. Methods 60 patients with chronic erosive gastritis admitted to our hospital from September 2021 to September 2023 were randomly divided into study group and control group, with 30 cases in each group. Patients in both groups received conventional treatment for chronic erosive gastritis, the control group was given esomeprazole, and the study group was given Rebaptiste combined with esomeprazole for continuous treatment for 2 weeks. The therapeutic effect and serum factor levels before and after treatment were evaluated and compared between the two groups. Results After treatment, the total effective rate of the study group was higher than that of the control group, and the levels of tumor necrosis factor-α, interleukin-6, interleukin-8 and other serum factors were lower than those of the control group, with statistical significance (P < 0.05). Conclusion In the treatment of chronic erosive gastritis, the combination of Rebabapide and esomeprazole is of great value in improving the curative effect and serum factor level.
|
| 关键词 |
慢性糜烂性胃炎；瑞巴派特；艾司奥美拉唑；疗效；血清因子
Chronic erosive gastritis; Rebabapide; Esomeprazole; Curative effect; Serum factor
|
| 基金项目 | |
| 页码 | 1-4 |